Annals of Oncology Advance Access published online on June 9, 2008
Annals of Oncology, doi:10.1093/annonc/mdn376
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials
1 Department of Internal Medicine
2 German Hodgkin Study Group, University Hospital Cologne, Cologne, Germany
* Correspondence to: Dr M. Sieniawski, Department of Internal Medicine, University Hospital Cologne, Kerpener Strasse 62, 50937 Cologne, Germany. Tel: +49-221-4785933; Fax: +49-221-4783778; E-mail: michal.sieniawski{at}ncl.ac.uk
Background: Infertility is one of the most significant side-effects in long-term survivors of successfully treated Hodgkin's lymphoma (HL).
Patients and methods: The fertility status was assessed in male HL patients enrolled into trials of the German Hodgkin Study Group from 1988 to 2003.
Results: In pre-treatment analysis (n = 202), 20% of patients had normozoospermia, 11% azoospermia and 69% had other dyspermia. In post-treatment analysis (n = 112), 64% of patients had azoospermia, 30% other dyspermia and 6% normozoospermia (P < 0.001). Azoospermia was observed in 90% of patients treated with chemotherapy alone, 67% of those treated with combined modality and 11% of those treated with radiotherapy alone (P < 0.001). Azoospermia was more frequent after 4x cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, vinblastine, dacarbazine (COPP/ABVD) (91%), 8x bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone (BEACOPP) baseline (93%) and 8x BEACOPP escalated (87%) compared with 2x COPP/ABVD (56%; P = 0.003). There was a statistically significant difference in post-treatment follicle-stimulating hormone (FSH) levels between patients with azoospermia and those with preserved spermatogenesis (P = 0.001).
Conclusions: Depending on the treatment received, male HL patients are at high risk of infertility after treatment. FSH might be used as surrogate parameter for male fertility in future studies.
chemotherapy, follicle-stimulating hormone, Hodgkin's lymphoma, male fertility
Received for publication April 29, 2008. Accepted for publication May 2, 2008.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Engert, V. Diehl, J. Franklin, A. Lohri, B. Dorken, W.-D. Ludwig, P. Koch, M. Hanel, M. Pfreundschuh, M. Wilhelm, et al. Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study J. Clin. Oncol., September 20, 2009; 27(27): 4548 - 4554. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Rennert, H. S. Rennert, M. Pinchev, O. Lavie, and S. B. Gruber Use of Hormone Replacement Therapy and the Risk of Colorectal Cancer J. Clin. Oncol., September 20, 2009; 27(27): 4542 - 4547. [Abstract] [Full Text] [PDF]
|
|